Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Diagnosis and treatment of Alzheimer disease

a technology for alzheimer's and diagnosis, applied in the direction of bacteria, antibacterial agents, peptide/protein ingredients, etc., can solve the problems of lack of sensitivity required for detecting early stage or low level infections, syphilis does not account for the binding of some antibodies to complexes formed, and is not generally used as a diagnosti

Inactive Publication Date: 2006-11-30
BIOKIT
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

Enhances the sensitivity of diagnostic assays and provides a mechanism for inhibiting pathogen infections by targeting the Tp17-lysozyme interaction, improving the detection of antibodies and treating infections through the use of mutant lysozyme polypeptides.

Problems solved by technology

This test is not generally used as a diagnostic due to its high cost.
Although these assays are widely used, they lack the sensitivity required for detecting early stage or low level infection, when Tp antibody levels in the body fluids are very low.
In addition, the popular use of individual recombinant or purified Tp antigens in existing immunoassays for syphilis does not account for the binding by some antibodies to complexes formed between Tp antigens and other antigens (i.e., Tp antigen binding partners) normally present in the subject's body fluid.
Existing immunoassays thus fail to detect such antibodies in the absence of the Tp antigen binding partner, which results in some instances in low sensitivity or false negative assay results.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Diagnosis and treatment of Alzheimer disease
  • Diagnosis and treatment of Alzheimer disease
  • Diagnosis and treatment of Alzheimer disease

Examples

Experimental program
Comparison scheme
Effect test

example 1

Chicken Lysozyme Copurifies with Recombinant Forms of the Treponema Pallidum 17 kDa Antigen

[0232] In the context of purifying E. coli-derived, recombinant T. pallidum Tp17 antigen (GST-Tp17 or Tp17-HIS), a protein reproducibly co-purified with Tp17. This “contaminant” protein, which had a molecular weight of 14 KDa and did not react with an anti-Tp17 polyclonal serum, was identified as chicken lysozyme as described below.

[0233] A protein fraction containing both entities (Tp17 and the “contaminant”) was separated by PAGE-SDS, excised from the gel and subjected to N-terminal amino acid sequencing. The experiment yielded short N-terminal peptide sequences (6-7 amino acids) that matched perfectly with the expected sequence of the T. pallidum Tp17 antigen or chicken lysozyme, which was included in the cell paste resuspension buffer to facilitate bacterial cell lysis. These observations suggested that Tp17 interacts physically with chicken lysozyme. Experimental protocols corresponding...

example 2

Far Western Detection of Tp17 Binding to Chicken and Human Lysozyme

[0245] The observation that the T. pallidum 17 kDa (Tp17) protein antigen copurifies with chicken lysozyme strongly suggested a direct physical interaction between both proteins. In order to test this hypothesis, a Far-Western blot lysozyme-protein interaction assay was performed. The assay is summarized in FIG. 5 and comprises generally the following three steps: (1) immobilization of purified lysozyme onto a membrane; (2) probing of the membrane with a ligand likely to bind directly to the lysozyme; and (3) immunodetection of the bound lysozyme-ligand. A detailed experimental procedure is presented below.

[0246] Far Western Blotting Detection of Lysozyme-Tp17 Protein Interactions

[0247] Purified chicken egg white lysozyme and human breast milk lysozyme were purchased from Sigma-Aldrich (Madrid, Spain). Two series of aliquot fractions containing 1 μg, 5 μg, and 10 μg of purified lysozyme and a protein molecular wei...

example 3

The T. Pallidum Tp17 Protein Antigen Inhibits the Antibacterial Activity of Chicken and Human Lysozyme

[0249] Lysozymes are well characterized antibacterial agents found on mucosal surfaces and in biological fluids. Due to their potent acetyl-muramidase enzymatic activity, lysozymes are capable of hydrolyzing cell wall peptidoglycan, thereby killing many pathogenic bacteria. The strong binding between Tp17 and human lysozyme suggested that this binding may alter the antibacterial activity of lysozyme. This hypothesis is consistent with the observation that (i) T. pallidum is a mucosal pathogen and (ii) it is in contact with human lysozyme in its ecological niche, throughout its infectious life cycle.

[0250] To test this hypothesis, the antibacterial activity of both human and chicken lysozyme, in the presence or absence of GST-Tp17, was assayed using an EnzCheck® lysozyme assay kit (Molecular Probes, Eugene, Oreg.). The assay comprises the use of Fluorescein-labeled Micrococcus lyso...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
molar ratioaaaaaaaaaa
molar ratioaaaaaaaaaa
molar ratioaaaaaaaaaa
Login to View More

Abstract

The present invention generally features therapeutic and diagnostic compositions and methods for increasing or decreasing the binding of a lysozyme polypeptide to a Treponema pallidum P17 polypeptide (Tp17) or a Tp17-like polypeptide. More particularly, the invention relates to compositions and methods for detecting, treating, or preventing a pathogen infection or a chronic disorder; and to binding assays using a Tp17-like polypeptide and a lysozyme polypeptide.

Description

REFERENCE TO RELATED APPLICATIONS [0001] This application is a divisional application of U.S. Ser. No. 11 / 116,144, filed Apr. 27, 2005, which claims the benefit of International Application No. PCT / ES2004 / 000581, filed Dec. 23, 2004, which claims priority to European Patent Application No. EP 03 380 307.3, filed Dec. 23, 2003, the entire contents of each of which are incorporated by reference into the present application.FIELD OF THE INVENTION [0002] The present invention generally features diagnostic and therapeutic compositions and methods derived from the characterization of the binding of a lysozyme polypeptide to a Treponema pallidum P17 polypeptide (Tp17) or Tp17-like polypeptides. In addition, the invention provides methods and compositions for increasing or decreasing the binding between a lysozyme and a TP-17 or a TP-17 like polypeptide. BACKGROUND OF THE INVENTION [0003] Syphilis is a disease caused by Treponema pallidum (hereinafter also referred to as “Tp”) infection. Th...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): C07K14/20G01N33/554C07H21/04C12N1/21G01N33/569C12N15/74A61K38/16C12N9/36
CPCA61K38/164G01N2800/347C12N9/2462G01N33/56911G01N33/56983G01N33/571G01N33/573G01N2333/20G01N2333/924G01N2469/20G01N2500/02G01N2800/065G01N2800/24G01N2800/2821C07K14/20A61P1/02A61P1/04A61P11/00A61P11/16A61P13/12A61P15/02A61P15/16A61P15/18A61P25/28A61P27/16A61P29/00A61P31/00A61P31/04A61P31/06A61P31/14A61P31/16A61P31/18A61P31/20A61P31/22A61P33/06A61P35/00A61P35/02A61P37/04A61P37/08A61P43/00Y02A50/30
Inventor BERTHET, FRANCOISVAYREDA CASADEVALL, FRANCESCCRUZ SANZ MARIA, MARIAGARCIA, TERESAOLLE, ANGELS
Owner BIOKIT
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com